表紙:バンコマイシン耐性腸球菌感染症:パイプライン製品の分析
市場調査レポート
商品コード
264091

バンコマイシン耐性腸球菌感染症:パイプライン製品の分析

Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) - Drugs in Development, 2021

出版日: | 発行: Global Markets Direct | ページ情報: 英文 102 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.56円
バンコマイシン耐性腸球菌感染症:パイプライン製品の分析
出版日: 2021年09月30日
発行: Global Markets Direct
ページ情報: 英文 102 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

バンコマイシン耐性腸球菌の病原性株は、VREと呼ばれ、院内感染の原因となっています。症状は、感染部位によって異なります。細菌は通常、腸・創傷・尿路で感染します。創傷感染の場合は、感染部位は赤く、圧痛があり、腫れます。尿路感染の場合は、背中の痛み、排尿時の灼熱感が生じます。他には、悪心、発熱、悪寒、激しい頭痛、下痢などの症状が見られます。予防には、効果的な衛生の実行が不可欠です。

当レポートでは、バンコマイシン耐性腸球菌感染症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

バンコマイシン耐性腸球菌感染症の概要

治療薬の開発

  • パイプライン製品の概要
  • 企業別のパイプライン
  • 大学/研究機関で開発されたパイプライン
  • 企業で開発中の製品
  • 大学/研究機関で開発中の製品

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • Alchemia Ltd
  • Aphios Corp
  • C3J Therapeutics Inc
  • Helix BioMedix Inc
  • Hsiri Therapeutics LLC
  • LegoChem Biosciences Inc
  • Lytix Biopharma AS
  • MGB Biopharma Ltd
  • MicuRx Pharmaceuticals Inc
  • Nanotherapeutics Inc
  • NovoBiotic Pharmaceuticals LLC
  • Oragenics Inc
  • Ovensa Inc
  • Sealife PHARMA GMBH
  • Wockhardt Ltd

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

List of Tables

List of Tables

  • Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Companies, 2021 (Contd..1)
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Acurx Pharmaceuticals Inc, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by AimMax Therapeutics Inc, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by AnyGen Co Ltd, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Aphios Corp, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Arietis Corp, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Curza Global LLC, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Daiichi Sankyo Co Ltd, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Hsiri Therapeutics LLC, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Karveel Pharmaceuticals, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by LegoChem Biosciences Inc, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MGB Biopharma Ltd, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MicuRx Pharmaceuticals Inc, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Naicons Srl, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by NovoBiotic Pharmaceuticals LLC, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Opal Biosciences Ltd, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Oragenics Inc, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by QureTech Bio AB, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Rebiotix Inc, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sano Chemicals Inc, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sentinella Pharmaceuticals Inc, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Wockhardt Ltd, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects, 2021 (Contd..1)
  • Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
目次
Product Code: GMDHC13096IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Enterococcus faecium Infections - Drugs In Development, 2021, provides an overview of the Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline landscape.Pathogenic strains of Enterococcus resistant to vancomycin are termed as Vancomycin-Resistant Enterococcus (VRE). Vancomycin-resistant enterococci have become a source of nosocomial infections. The symptoms of Vancomycin-resistant enterococci infection depend on where the infection lies. The bacteria usually infect the intestines, wounds and urinary tract. In case of wound infection, the area infected will be red and tender as well as swollen. In case of urinary tract infection, back pain and burning could occur when urination takes place. Other symptoms include nausea, fever, chills, severe headaches and diarrhea. Prevention requires effective hygienic practices.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vancomycin-Resistant Enterococcus faecium Infections - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Vancomycin-Resistant Enterococcus faecium Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 1, 13 and 9 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 2 molecules, respectively.

Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Vancomycin-Resistant Enterococcus faecium Infections - Overview
  • Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics Development
  • Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics Assessment
  • Vancomycin-Resistant Enterococcus faecium Infections - Companies Involved in Therapeutics Development
  • Vancomycin-Resistant Enterococcus faecium Infections - Drug Profiles
  • Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects
  • Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products
  • Vancomycin-Resistant Enterococcus faecium Infections - Product Development Milestones
  • Appendix